Schizophrenia

May 02, 2018

Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting

Apr 26, 2018

SOTERIA and CureMatch Partner to Support Oncologists with Personalized Cancer Treatment Options

Apr 24, 2018

Feinstein Institute researcher nominated to Association of American Physicians

Mar 12, 2018

Global Schizophrenia Treatment Market to Reach US$ 2600 Mn by 2027 - Persistence Market Research

Feb 09, 2018

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials

Jan 18, 2018

New Real World Evidence Shows that Long-acting Antipsychotics Reduce Risk of Mortality for Patients Living with Schizophrenia Compared to Oral Antipsychotics

Dec 12, 2017

Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot

Nov 13, 2017

Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia

Nov 10, 2017

Rising Competition for Treating Positive Symptoms of Schizophrenia Requires Companies to Focus on Therapies for Negative and Cognitive Symptoms

Sep 13, 2017

Industry Veteran Dr. Ashley Brenton joins SOTERIA as VP of Translational Medicine

Jul 21, 2017

IBM and University of Alberta publish new data on machine learning algorithms to help predict schizophrenia

Jun 20, 2017

Soteria Intelligence Develops AI-Powered Counter-Terrorism Solution, Expands Focus on Marketing/PR Industry